Olmesartan Medoxomilo Sandoz

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo Sandoz, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is used to manage high blood pressure in adult patients. GNH USA supplies Olmesartan Medoxomilo Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxomilo Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil is an ARB that acts on the renin‑angiotensin system to lower blood pressure. - Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes. - Heart failure: used as part of combination therapy to improve symptoms and outcomes.

Adverse reactions reported with olmesartan medoxil vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhoea - Upper respiratory tract infection

Serious or Rare Side Effects: - Angio‑edema involving the face, lips, tongue or airway - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevations - Bullous skin reactions (e.g., Stevens‑Johnson syndrome)

When prescribing olmesartan medoxil, clinicians should consider several safety aspects. - Renal function monitoring: assess baseline creatinine and eGFR, then periodically. - Electrolyte balance: check serum potassium, especially if combined with potassium‑sparing diuretics. - Pregnancy: avoid use during the second and third trimesters due to fetal toxicity. - Concomitant NSAIDs: may reduce antihypertensive effect and affect kidney function. - Hypotension risk: caution in volume‑depleted patients or those on other antihypertensives. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil may interact with several medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid): - Aliskiren (combined use in diabetic patients is contraindicated). - Potassium‑supplement containing products (risk of hyper‑kalemia). - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs).

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may blunt antihypertensive response. - Lithium – increased lithium levels and potential toxicity. - Cyclosporine or tacrolimus – may raise serum creatinine. - Diuretics – additive blood‑pressure lowering effect, monitor for hypotension.